Future, Innovation
Our projects aim to improve quality of life and promote a healthier and more sustainable future.
At Byotic, we drive progress in biotechnology through innovative projects covering a variety of health-related fields and sectors. Our initiatives are designed to significantly improve people's quality of life and promote a healthier, more sustainable future. Through pioneering solutions, we focus our efforts on addressing current and future challenges, thus contributing to global well-being.
1
Pt-Adsorber: A Filter for Metal Retention in Apheresis Processes
A novel approach to mitigate the side effects of chemotherapy, specifically by reducing toxic platinum levels after treatment
2
Bioreactor Platforms for Advanced Therapies
Innovative technology in the field of single-use bioreactors for the production of cell therapy products.
Pt-Adsorber
Adsorptive column for heavy metal retention in plasma
Chemotherapy is a fundamental tool in the fight against cancer; however, its application often comes with undesirable side effects. One of the main challenges is the persistence of toxic metals, such as platinum (Pt2+), in the body after treatment. These heavy metals can cause organ damage and lead to severe side effects such as nephrotoxicity, hepatotoxicity, and neurotoxicity. To address this issue, Byotic has developed a promising prototype specifically designed for the selective retention of metals, with a particular focus on platinum. This initiative aims to reduce toxic levels of platinum after chemotherapy, improving the quality of life for post-oncological patients and potentially enhancing the efficacy of treatment in severe cancer cases.
The main objective of this project is to investigate and evaluate the efficacy of this prototype in metal retention through therapeutic apheresis. The prototype features a selective adsorbent column for platinum (Pt2+) made from a new biomaterial.
Apheresis is an extracorporeal filtration method used to remove unwanted substances from the blood. It is a medical procedure that allows for the separation of a specific component from a blood sample. This process can be used for various medical purposes, such as blood donations, disease treatment, and research.
Interview with Dr. Joan Cid
Learn everything about apheresis with Byotic
In this interview, Dr. Joan Cid, director of the therapeutic apheresis unit at Hospital Clínic de Barcelona, explains what apheresis is, how it is performed, and why it is important, with a focus on bioengineering for public health.
To achieve the project's overall goal, preclinical studies using porcine models have been conducted.
This project, co-funded by the Center for Industrial Technological Development (CDTI) of Spain's Ministry of Economy and Competitiveness, marks a significant milestone in Byotic's research and development. Although there are challenges, such as developing a porcine xenotransplant model and assessing the viability of apheresis in these animal models, this innovative initiative has the potential to not only improve the quality of life for cancer patients but also to lay the groundwork for more effective treatments.
Development of bioreactor platforms for autologous cell therapies
In the framework of the recovery, transformation, and resilience plan (PRTR) financed by the recovery and resilience mechanism (MRR), an ambitious Pre-Commercial Public Procurement project has been launched in Spain. This project, led by the joint venture TECNIC-BYOTIC, aims to develop innovative technology in the field of single-use bioreactors for the production of drugs based on autologous cells, intended to revolutionize personalized cell therapies.
The technological challenge and urgent need
Autologous cell therapies represent an advanced form of personalized medicine, where the patient's own cells are used to develop specific therapies. In Spain, the demand for these treatments is increasing within the National Health System (SNS), driven by their ability to address diseases in a personalized and effective manner.
However, the handling of these cells in SNS hospitals varies and is not standardized, depending on the type of cell and the technology available at each center. This lack of uniformity not only affects the efficiency and quality of therapies but also increases costs and limits the capacity to scale production to meet the growing national demand.
Additionally, there is a notable reliance on imported technology due to the scarcity of biotechnology companies in Spain with the capability to develop advanced single-use bioreactor systems. This situation not only increases production costs but also restricts the country's ability to innovate and lead in a promising field such as personalized biopharmaceuticals.
​
Impact and future prospects
This project aims not only to meet the internal demand for personalized cell therapies in Spain but also to position the country as a leader in the research and development of advanced biopharmaceutical technologies.
An innovative and collaborative solution.
​​
To address these challenges, the companies TECNIC and BYOTIC have established a strategic collaboration by forming a joint venture, in partnership with renowned public institutions such as the Autonomous University of Barcelona (UAB) and the Banc de Sang i Teixits de Catalunya (BST). This collaborative network integrates expertise in process engineering and biotechnology to develop a new generation of technology. The project focuses on three key subsystems: a new intelligent single-use bioreactor, an intelligent platform for parallel bioreactor management, and an intelligent platform for the transfer of best practices. These components are designed to function in an integrated manner and optimize the production of drugs based on autologous cells in hospital environments.
The goal is to advance the technology readiness level from TRL 4 (technology validated in the laboratory) to TRL 7 (prototype demonstration in an operational environment). This will involve not only the design and development of advanced prototypes but also their validation in real operational conditions, thereby facilitating their widespread adoption in the National Health System (SNS) and other biopharmaceutical environments.
​
In Byotic
We transform your R&D into a real product.
We want to support your project, turn it into a
viable solution and open the doors to the market.